FDA Announces Plan for Expedited Review of Certain Medical Devices

05 May 2014 Health Care Law Today Blog

The Food and Drug Administration (FDA) published proposed guidance on April 22nd for a voluntary expedited access program for new high-risk medical devices that are intended to treat or diagnose patients with serious conditions that are unaddressed by approved technology. The guidance, titled “Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Disease or Conditions” (EAP), is characterized by the agency as an attempt to “help patients have more timely access to these medical devices by expediting their development, assessment and review, while preserving the statutory standard of reasonable assurance of safety and effectiveness…” The FDA also noted that the EAP program is not necessarily a new pathway to market, but instead a collaborative approach between the agency and manufacturers to accelerate device availability under the agency’s existing regulations by speeding both development and pre-market review. The EAP program contains features from its Innovation Pathway program, which was piloted by the agency in 2011. An important feature of the guidance is that the FDA intends to work interactively with qualifying device sponsors to develop device-specific data development plans that will outline the data that sponsors intend to collect in support of ultimate device approval.

To qualify for the EAP process, a device must meet the following conditions:

  • The device must be intended to treat or diagnose a life-threatening or irreversibly-debilitating disease or condition;
  • The device must represent one of the following:
    • No approved alternative treatment/diagnostic exists, or
    • A breakthrough technology that provides a clinically meaningful advantage over existing technology, or
    • Offers a significant, clinically meaningful advantage over existing approved alternatives, or
    • Availability is in the patient’s best interest;
  • The device must have an acceptable data development plan that has been approved by the FDA.

The proposed guidance is open for public comment for ninety (90) days following publication in the Federal Register on April 23, 2014. 

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights